menu
    • menu

    Company profile for Annovis Bio

    NEW Drugs in Dev: 2
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death. With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Annovis understands how the brain works and how brain cells die. Nerve cell death is the underlying cause of all neur...
    Our drug attacks neurodegeneration by improving axonal transport, the information highway of the nerve cell, which has been shown to be the cause of nerve cell degeneration and ultimately death. With an aging population, neurodegenerative diseases have become one of the world’s largest unmet medical needs. Annovis understands how the brain works and how brain cells die. Nerve cell death is the underlying cause of all neurodegenerative disease in both slow chronic and fast acute injuries to the brain

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Annovis BioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1055 Westlakes Drive Suite 300 Berwyn, PA 19312
    Telephone
    Telephone
    +1 (610) 727-3913
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.annovisbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Annovis Prices $15M Public Offering with Warrants
    Annovis Prices $15M Public Offering with Warrants

    20 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/20/3298420/0/en/annovis-announces-pricing-of-15-0-million-public-offering-of-common-stock-and-accompanying-warrants.html

    GLOBENEWSWIRE
    20 May 2026
    Share Share
    Annovis Announces Public Offering of Stock and Warrants
    Annovis Announces Public Offering of Stock and Warrants

    19 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/19/3297958/0/en/annovis-announces-launch-of-proposed-public-offering-of-common-stock-and-accompanying-warrants.html

    GLOBENEWSWIRE
    19 May 2026
    Share Share
    Annovis Reports Q1 2026 Financial Results
    Annovis Reports Q1 2026 Financial Results

    15 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/15/3295755/0/en/annovis-provides-corporate-updates-and-reports-first-quarter-2026-financial-results.html

    GLOBENEWSWIRE
    15 May 2026
    Share Share
    Annovis Releases Alzheimer's Phase 2/3 Trial Results In Nature
    Annovis Releases Alzheimer's Phase 2/3 Trial Results In Nature

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282572/0/en/annovis-publishes-phase-2-3-alzheimer-s-trial-results-in-nature-portfolio.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share
    Annovis Raises $10M for Ph 3 Alzheimer Disease's NDA Submission
    Annovis Raises $10M for Ph 3 Alzheimer Disease's NDA Submission

    10 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/10/3271713/0/en/Annovis-Closes-10-Million-Offering-Extending-Cash-Runway-Through-Phase-3-Alzheimer-s-Disease-6-Month-NDA-Submission.html

    GLOBENEWSWIRE
    10 Apr 2026
    Share Share
    Annovis Launches $10M Common Stock Offering With Warrants
    Annovis Launches $10M Common Stock Offering With Warrants

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270958/0/en/Annovis-Announces-10-Million-Underwritten-Offering-of-Common-Stock-and-Accompanying-Warrants.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search